News
Drugmaker Gilead Sciences is not only providing the shot in the US, but is also working with governments and health groups in the UK and low-income countries to make these products more available.
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
The risk for MACEs was higher among patients with HIV infection receiving abacavir- vs tenofovir-based ART regimens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback